These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1024 related articles for article (PubMed ID: 22659190)

  • 1. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
    Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Landrum LM; Brady WE; Armstrong DK; Moore KN; DiSilvestro PA; O'Malley DM; Tenney ME; Rose PG; Fracasso PM
    Gynecol Oncol; 2016 Feb; 140(2):204-9. PubMed ID: 26616225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
    Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
    Richardson DL; Moore KN; Vergote I; Gilbert L; Martin LP; Mantia-Smaldone GM; Castro CM; Provencher D; Matulonis UA; Stec J; Wang Y; Method M; O'Malley DM
    Gynecol Oncol; 2024 Jun; 185():186-193. PubMed ID: 38447347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
    J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
    Wenham RM; Lapolla J; Lin HY; Apte SM; Lancaster JM; Judson PL; Gonzalez-Bosquet J; Herschberger A; Havrilesky LJ; Secord AA
    Gynecol Oncol; 2013 Jul; 130(1):19-24. PubMed ID: 23623830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety and efficacy of pegylated liposomal Doxorubicin and Carboplatin on platinum-sensitive recurrent epithelial ovarian cancer].
    Nishio S; Ushijima K; Shimizu T; Tachibana T; Nasu H; Aiko K; Kawano R; Kurokawa Y; Sumino Y; Yokomine M; Takemoto S; Kamura T
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2539-43. PubMed ID: 24335366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
    Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
    Thaker PH; Brady WE; Lankes HA; Odunsi K; Bradley WH; Moore KN; Muller CY; Anwer K; Schilder RJ; Alvarez RD; Fracasso PM
    Gynecol Oncol; 2017 Nov; 147(2):283-290. PubMed ID: 28802766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.